Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.64 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856302 | 0.90 | MCHR1 (0.51) | MCHR1ACACBCYP1A2EBPSIGMAR1 | |
| SCHEMBL3859101 | 0.89 | MCHR1 (0.53) | MCHR1ACACBCYP1A2CYP2D6EBP | |
| SCHEMBL10970158 | 0.81 | MCHR1 (0.91) | MCHR1ACACBCYP1A2CYP2D6EBP | |
| SCHEMBL13683745 | 0.81 | MCHR1 (0.93) | MCHR1CYP1A2CYP2D6EBPSIGMAR1 | |
| SCHEMBL28290037 | 0.79 | NPSR1 (0.57) | CYP1A2CYP3A4 | |
| SCHEMBL3857792 | 0.78 | MCHR1 (0.46) | MCHR1ACACBEBPSIGMAR1MAOB | |
| SCHEMBL3861887 | 0.77 | MCHR1 (0.59) | MCHR1ACACBCYP1A2CYP2D6CYP3A4 | |
| SCHEMBL13683422 | 0.75 | MCHR1 (0.43) | MCHR1ACACBEBPSIGMAR1MAOB | |
| SCHEMBL28291465 | 0.74 | NPSR1 (0.54) | ACACB | |
| SCHEMBL10676256 | 0.72 | MCHR1 (0.60) | MCHR1CYP1A2CYP2D6EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | MCHR1 1/4885ACACB 992/4885CYP1A2 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.